Tuesday in Philadelphia, at the World Drug Safety Congress 2019 (April 16-17), Asymmetrex introduces its AlphaSTEM Test™ to the international pharmaceutical community. By early detection of drug candidates that are stem cell-toxic, Asymmetrex can eliminate drugs that will fail late after great cost because they induce chronic organ failure. By assaying for toxic effects on organ and tissue stem cells specifically, very bad drugs can be identified sooner, without injuring patients, and at greatly reduced development cost. Spend 2 minutes learning more about the technology that Asymmetrex is introducing. #WeCountStemCells…Specifically!
Leave a Reply